Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice (Q34157402)

31 July 2017

1 reference

title

Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice (English)

1 reference

31 July 2017

1

Massimo Franchini

1 reference

31 July 2017

Pier Mannuccio Mannucci

series ordinal

2

object named as

Pier Mannuccio Mannucci

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

British Journal of Clinical Pharmacology

31 July 2017

published in

1 reference

31 July 2017

volume

72

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

553-562

1 reference

Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Recombinant activated factor VII: mechanisms of action and current indications

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Clinical issues in inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

The multifactorial etiology of inhibitor development in hemophilia: genetics and environment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Advances in the understanding of acquired haemophilia A: implications for clinical practice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

International recommendations on the diagnosis and treatment of patients with acquired hemophilia A

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Back to the future: a recent history of haemophilia treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Laboratory, clinical and therapeutic aspects of acquired hemophilia A.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Acquired factor VIII inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Inhibitors in haemophilia A: current management and open issues

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

International workshop on immune tolerance induction: consensus recommendations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Treatment of acquired hemophilia A.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Rituximab in the treatment of adult acquired hemophilia A: a systematic review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Postpartum acquired factor VIII inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Inhibitors to Factor XI in patients with severe Factor XI deficiency

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Acquired hemophilia A: a concise review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Inhibitors in congenital coagulation disorders

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

The epidemiology of inhibitors in haemophilia A: a systematic review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Treatment of the bleeding inhibitor patient

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Acquired factor VIII autoantibody inhibitors: current concepts and potential therapeutic strategies for the future

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Anaphylaxis in patients with hemophilia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Inhibitor antibodies to factor VIII and factor IX: management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

The role of genetics in inhibitor formation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Successful Treatment of Acquired Hemophilia with Oral Immunosuppressive Therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

DDAVP in acquired hemophilia A: case report and review of the literature

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

5 July 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Gene mutations and inhibitor formation in patients with hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Management of haemophilia B patients with inhibitors and anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

International survey of attitudes towards secondary prophylaxis with recombinant factor VIIa in haemophilia A patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Extracorporeal immunoadsorption for the treatment of coagulation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Tolerance induction using the Malmö treatment model 1982-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Comparison of the international immune tolerance registry and the North American immune tolerance registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

The international immune tolerance study: a multicenter prospective randomized trial in progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

A population based, unselected, consecutive cohort of patients with acquired haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Treatment of acquired haemophilia with factor eight inhibitor bypassing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2125.2010.03899.X

Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

The German Registry of immune tolerance treatment in hemophilia--1999 update.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195733

Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency

28 October 2018

1 reference

12 December 2020

Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide

1 reference

12 December 2020

Corticosteroid therapy for acquired F VIII:C inhibitors

1 reference

12 December 2020

A survey of 215 non-hemophilic patients with inhibitors to Factor VIII

1 reference

12 December 2020

A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies

1 reference

12 December 2020

The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study

1 reference

12 December 2020

Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial

1 reference

12 December 2020

Safety of Recombinant Activated Factor VII in Randomized Clinical Trials

1 reference

12 December 2020

10.1111/J.1365-2125.2010.03899.X

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference